ANG-PD

$21.01-2.32%

American National Group Inc.

Market Cap

$210,100

Live price × SEC shares (Aug 12, 2026)

Sector

Financials

Industry

Life Insurance

Beta (raw)

—

Insufficient price history

P/E (TTM)

0.0

TTM to Jun 2026 · mkt cap / net income

P/S (TTM)

0.0

TTM to Jun 2026 · revenue

P/B

0.0

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD millions	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	2,058	904	1,600	1,706	6,268
Total operating expenses	156	78	206	230	670
Interest expense	47	43	49	42	181
Pretax income	337	123	20	280	760
Income tax	119	(122)	17	72	86
Net income	219	368	(1)	204	790

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in millions. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

8 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Sep 15, 2026 accepted 4:28 PM ET	8.01Other events	Document SEC ↗
Aug 26, 2026 accepted 12:00 PM ET	2.02Earnings release	Document SEC ↗
Jun 15, 2026 accepted 4:33 PM ET	8.01Other events	Document SEC ↗
May 22, 2026 accepted 11:04 AM ET	2.02Earnings release	Document SEC ↗
Apr 9, 2026 accepted 11:36 AM ET	2.02Earnings release	Document SEC ↗
Mar 17, 2026 accepted 4:07 PM ET	8.01Other events	Document SEC ↗
Dec 15, 2025 accepted 4:06 PM ET	8.01Other events	Document SEC ↗
Nov 21, 2025 accepted 12:26 PM ET	2.02Earnings release	Document SEC ↗
Oct 7, 2025 accepted 4:58 PM ET	2.01Acquisition / disposition	Document SEC ↗
Oct 6, 2025 accepted 4:15 PM ET	8.01Other events	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

—

of daily vol

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

No Form 4 transactions on record.

Recent News

NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC

OncLive · 2026-10-30

AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer

AstraZeneca · 2026-09-28

Novel B7H3 ADC Yields Responses in Cervical Cancer and Platinum-Resistant Ovarian Cancer

CancerNetwork · 2026-04-12

PD-1 and PD-L1 Inhibitor Market to Hit USD 62.23 Bn in 2025 Amid Rising Cancer Burden

BioSpace · 2025-06-13

American National Group Inc. (ANG-PD) Company Profile & Facts - Yahoo Finance

Yahoo! Finance Canada · 2025-01-20

Impact of PD-1 and PD-L1 Expression on Overall Survival in Patients With NSCLC and Melanoma

Pharmacy Times · 2024-08-14

PD Stock Price and Chart — NYSE:PD

TradingView · 2019-04-11

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

Nature · 2009-09-09

Informational purposes only, not investment advice.

Corporate Events (8-K)

8 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Sep 15, 2026 accepted 4:28 PM ET	8.01Other events	Document SEC ↗
Aug 26, 2026 accepted 12:00 PM ET	2.02Earnings release	Document SEC ↗
Jun 15, 2026 accepted 4:33 PM ET	8.01Other events	Document SEC ↗
May 22, 2026 accepted 11:04 AM ET	2.02Earnings release	Document SEC ↗
Apr 9, 2026 accepted 11:36 AM ET	2.02Earnings release	Document SEC ↗
Mar 17, 2026 accepted 4:07 PM ET	8.01Other events	Document SEC ↗
Dec 15, 2025 accepted 4:06 PM ET	8.01Other events	Document SEC ↗
Nov 21, 2025 accepted 12:26 PM ET	2.02Earnings release	Document SEC ↗
Oct 7, 2025 accepted 4:58 PM ET	2.01Acquisition / disposition	Document SEC ↗
Oct 6, 2025 accepted 4:15 PM ET	8.01Other events	Document SEC ↗